Human Health Holdings Ltd. (1419) AI Stock Analysis

• Market Cap: HK$315.03M
• Dividend Yield: 3.37%
• Average Volume (3M): 31.00K
• Price to Earnings (P/E): 15.0
• Beta (1Y): 0.09
• Revenue Growth: -0.69%
• EPS Growth: N/A
• Country: HK
• Employees: 388
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Care Facilities
• EPS (TTM): 0.06
• Shares Outstanding: 379,552,220
• 10 Day Avg. Volume: 22,600
• 30 Day Avg. Volume: 31,000
• PEG Ratio: 2.98
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: HK$1.00 ▲(20.48%Upside)

The overall stock score is primarily influenced by financial performance challenges due to declining revenue and cash flow issues, despite a strong balance sheet. Technical analysis and valuation provide moderate support, indicating some market confidence, but the focus remains on addressing financial health concerns.

Human Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Human Health Holdings Limited, an investment holding company, provides healthcare services in Hong Kong. The company offers general practice services, including general consultation, diagnostics and preventative health, minor procedure, vaccination, physical check-up, health education, occupational health advisory, Chinese medicine, work injury assessment, telemedicine, COVID-19 related, outreach services, and healthcare related services and products. It also provides specialty services in the areas of general surgery, orthopedics and traumatology, ophthalmology, otorhinolaryngology, pediatrics, obstetrics and gynecology, gastroenterology and hepatology, respiratory medicine, cardiology, pediatric surgery, dermatology and venereology, psychiatry, radiology, urology, nephrology, neurosurgery, anaesthesiology, and oncology, as well as physiotherapy, clinical psychology, medical aesthetics, nutritionist, health and wellness, endoscopy, and medical diagnostics. In addition, the company offers dental services comprising general dentistry, dental implant, 3D guided implant surgery, crown and bridge, periodontal treatment, prosthodontics, oral surgery, orthodontics, endodontics, cosmetic dentistry, teeth whitening, veneers and laser dentistry, advanced oral and maxillofacial surgery, CAD/CAM dentistry, panoramic radiography, and cone-beam computed tomography services. Further, it provides doctors and dentists agreements management, and medical imaging services. As of June 30, 2021, the company operated 58 medical centers and 103 service points. The company was founded in 1997 and is headquartered in Kowloon, Hong Kong. Human Health Holdings Limited is a subsidiary of Treasure Group Global Limited.

How the Company Makes Money

Human Health Holdings Ltd. generates revenue primarily through the provision of medical and healthcare services at its network of clinics. The company earns money by charging fees for consultations, medical examinations, diagnostic tests, and treatment services provided to patients. Additionally, Human Health Holdings secures income from partnerships with corporate clients through health assessment programs and wellness services. The company's earnings are further supported by strategic collaborations with insurance companies, which facilitate access to a broader patient base and provide a steady stream of referrals.

Human Health Holdings Ltd. Financial Statement Overview

Summary

Human Health Holdings Ltd. faces financial difficulties, with declining revenue and net income significantly impacting the income statement and cash flow. Although the balance sheet shows low leverage and robust liquidity, the negative free cash flow and reduced operating cash flow raise concerns about sustainability without external financing.

Income Statement

The income statement shows a concerning trend with declining revenues and profits over the past year. Revenue fell by approximately 41% from the previous year, and net income dropped by 87%. Gross profit margin stands at 45.7% and net profit margin at 4.1%, indicating the company's ability to manage costs relative to its revenue. However, the steep decline in both revenue and net income highlights significant financial challenges.

Balance Sheet

The balance sheet remains relatively strong, with a low debt-to-equity ratio of 0.19 and an equity ratio of 72.6%, indicating a solid financial foundation with low leverage. The company maintains a strong cash position, evidenced by a net debt of -343 million, suggesting a healthy liquidity buffer. Despite these strengths, the decline in stockholders' equity from the previous year is a concern.

Cash Flow

Cash flow analysis reveals significant issues, with free cash flow turning negative (-28 million) from a positive position in the previous year, indicating potential liquidity challenges. The operating cash flow to net income ratio is low, highlighting inefficiencies in converting profits into cash. The sharp decline in operating cash flow further exacerbates concerns about the company's cash generation capabilities.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
611.42M	590.82M	1.00B	1.12B	654.71M	453.74M
	Gross Profit
279.63M	269.85M	593.24M	659.68M	376.69M	189.84M
	EBIT
88.81M	87.72M	307.07M	428.81M	146.06M	-18.59M
	EBITDA
37.19M	104.06M	323.46M	513.25M	238.36M	42.16M
	Net Income Common Stockholders
20.98M	24.19M	180.84M	375.31M	144.45M	-40.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
479.84M	489.58M	641.26M	270.33M	162.83M	137.19M
	Total Assets
1.03B	1.06B	1.26B	1.16B	612.39M	427.99M
	Total Debt
132.16M	146.46M	182.49M	188.47M	67.08M	102.17M
	Net Debt
-347.68M	-343.12M	-458.77M	-81.86M	-78.19M	-20.45M
	Total Liabilities
258.48M	289.71M	455.27M	416.67M	202.26M	168.94M
	Stockholders Equity
771.37M	766.67M	808.22M	741.95M	410.13M	259.05M
Cash Flow		Free Cash Flow
69.49M	-28.17M	580.24M	219.30M	71.44M	26.03M
	Operating Cash Flow
85.25M	11.34M	664.26M	295.81M	85.49M	37.50M
	Investing Cash Flow
201.63M	-47.63M	-335.34M	-203.22M	-4.77M	-18.99M
	Financing Cash Flow
-73.29M	-122.66M	-178.28M	-67.45M	-59.30M	-64.75M

Human Health Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1419, the sentiment is Positive. The current price of 0.83 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.79, and above the 200-day MA of 0.80, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.97 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1419.

Human Health Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1419	58 Neutral	HK$315.03M	15.01	2.73%	3.37%	-0.69%	―
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
BJTRF		$930.02M	8.46	12.58%	6.90%	―	―
LVZPF		$4.57B	13.22	14.56%	4.43%	―	―
1518	59 Neutral	HK$571.08M	11.01	8.82%	1.89%	-10.82%	-43.85%
2160	49 Neutral	HK$2.51B	―	-2.19%	―	5.32%	89.43%
3869	48 Neutral	HK$594.23M	―	-10.78%	―	-0.95%	-128.35%

Human Health Holdings Ltd. Corporate Events

Human Health Holdings Ltd. Enhances Internal Controls for Consultancy Agreement

Human Health Holdings Ltd. has issued a supplemental announcement regarding its Consultancy Agreement, focusing on internal control procedures for continuing connected transactions. The company has outlined measures to ensure that these transactions are conducted on normal commercial terms, including regular market research and audit committee reviews to determine professional fees, ensuring fairness and alignment with industry standards.